Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial
Background and Purpose: Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[March 2010]
|
| In: |
Stroke
Year: 2010, Jahrgang: 41, Heft: 3, Pages: 426-430 |
| ISSN: | 1524-4628 |
| DOI: | 10.1161/STROKEAHA.109.564781 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/STROKEAHA.109.564781 Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.564781 
|
| Verfasserangaben: | Pierre Amarenco, MD, Larry B. Goldstein, MD, Henrik Sillesen, MD, DMSc, Oscar Benavente, MD, Richard M. Zweifler, Alfred Callahan, III, MD, Michael G. Hennerici, MD, PhD, Justin A. Zivin, MD, PhD, and K. Michael A. Welch, MB, ChB, FRCP |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1751578380 | ||
| 003 | DE-627 | ||
| 005 | 20220819135712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210317s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/STROKEAHA.109.564781 |2 doi | |
| 035 | |a (DE-627)1751578380 | ||
| 035 | |a (DE-599)KXP1751578380 | ||
| 035 | |a (OCoLC)1341398639 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Amarenco, Pierre |e VerfasserIn |0 (DE-588)1155322851 |0 (DE-627)1016735049 |0 (DE-576)50154657X |4 aut | |
| 245 | 1 | 0 | |a Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease |b findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial |c Pierre Amarenco, MD, Larry B. Goldstein, MD, Henrik Sillesen, MD, DMSc, Oscar Benavente, MD, Richard M. Zweifler, Alfred Callahan, III, MD, Michael G. Hennerici, MD, PhD, Justin A. Zivin, MD, PhD, and K. Michael A. Welch, MB, ChB, FRCP |
| 264 | 1 | |c [March 2010] | |
| 300 | |b Diagramme | ||
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.03.2021 | ||
| 520 | |a Background and Purpose: Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients.Methods— A total of 4731 patients (mean age, 63 years) was randomized to 80 mg/day atorvastatin placebo. The rates of major coronary event, any CHD event, and any revascularization procedure were evaluated.Results— After 4.9 years of follow-up, the risks of a major coronary event and of any CHD end point in the placebo group were 5.1% and 8.6%, respectively. The rate of outcome of stroke decreased over time, whereas the major coronary event rate was stable. Relative to those having a large vessel-related stroke at baseline, those having a transient ischemic attack, hemorrhagic stroke, small vessel stroke, or a stroke of unknown cause had similar absolute rates for a first major coronary event and for any CHD event; transient ischemic attack, small vessel, and unknown cause groups had lower absolute revascularization procedure rates. Major coronary event, any CHD event, and any revascularization procedure rates were similarly reduced in all baseline stroke subtypes in the atorvastatin arm compared with placebo with no heterogeneity between groups.Conclusion— CHD risk can be substantially reduced by atorvastatin therapy in patients with recent stroke or transient ischemic attack regardless of stroke subtype. | ||
| 700 | 1 | |a Goldstein, Larry B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sillesen, Henrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benavente, Oscar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zweifler, Richard M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Callahan, Alfred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hennerici, Michael G. |d 1948- |e VerfasserIn |0 (DE-588)11587545X |0 (DE-627)077527704 |0 (DE-576)290126444 |4 aut | |
| 700 | 1 | |a Zivin, Justin A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Welch, K. Michael A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke |d New York, NY : Association, 1970 |g 41(2010), 3, Seite 426-430 |h Online-Ressource |w (DE-627)266879985 |w (DE-600)1467823-8 |w (DE-576)075145731 |x 1524-4628 |7 nnas |a Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial |
| 773 | 1 | 8 | |g volume:41 |g year:2010 |g number:3 |g pages:426-430 |g extent:5 |a Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial |
| 856 | 4 | 0 | |u https://doi.org/10.1161/STROKEAHA.109.564781 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.564781 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210317 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 11587545X |a Hennerici, Michael G. |m 11587545X:Hennerici, Michael G. |d 60000 |d 62700 |e 60000PH11587545X |e 62700PH11587545X |k 0/60000/ |k 1/60000/62700/ |p 7 | ||
| 999 | |a KXP-PPN1751578380 |e 3889980090 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"recId":"1751578380","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 17.03.2021"],"title":[{"subtitle":"findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial","title":"Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease","title_sort":"Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease"}],"person":[{"roleDisplay":"VerfasserIn","display":"Amarenco, Pierre","role":"aut","family":"Amarenco","given":"Pierre"},{"given":"Larry B.","family":"Goldstein","role":"aut","display":"Goldstein, Larry B.","roleDisplay":"VerfasserIn"},{"given":"Henrik","family":"Sillesen","role":"aut","roleDisplay":"VerfasserIn","display":"Sillesen, Henrik"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Benavente, Oscar","given":"Oscar","family":"Benavente"},{"family":"Zweifler","given":"Richard M.","display":"Zweifler, Richard M.","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Callahan, Alfred","given":"Alfred","family":"Callahan"},{"given":"Michael G.","family":"Hennerici","role":"aut","roleDisplay":"VerfasserIn","display":"Hennerici, Michael G."},{"roleDisplay":"VerfasserIn","display":"Zivin, Justin A.","role":"aut","family":"Zivin","given":"Justin A."},{"given":"K. Michael A.","family":"Welch","role":"aut","roleDisplay":"VerfasserIn","display":"Welch, K. Michael A."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1970-","publisher":"Association ; Lippincott Williams & Wilkins","dateIssuedKey":"1970","publisherPlace":"New York, NY ; Philadelphia, Pa."}],"id":{"issn":["1524-4628"],"eki":["266879985"],"zdb":["1467823-8"]},"pubHistory":["1.1970 -"],"part":{"issue":"3","pages":"426-430","year":"2010","extent":"5","text":"41(2010), 3, Seite 426-430","volume":"41"},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 29.06.04"],"disp":"Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trialStroke","recId":"266879985","corporate":[{"role":"isb","display":"American Heart Association","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"title":[{"title":"Stroke","subtitle":"journal of the American Heart Association","title_sort":"Stroke"}]}],"physDesc":[{"extent":"5 S.","noteIll":"Diagramme"}],"id":{"doi":["10.1161/STROKEAHA.109.564781"],"eki":["1751578380"]},"origin":[{"dateIssuedDisp":"[March 2010]","dateIssuedKey":"2010"}],"name":{"displayForm":["Pierre Amarenco, MD, Larry B. Goldstein, MD, Henrik Sillesen, MD, DMSc, Oscar Benavente, MD, Richard M. Zweifler, Alfred Callahan, III, MD, Michael G. Hennerici, MD, PhD, Justin A. Zivin, MD, PhD, and K. Michael A. Welch, MB, ChB, FRCP"]}} | ||
| SRT | |a AMARENCOPICORONARYHE2010 | ||